Portfolio News
Ochre Bio signs $1.3B deal with Boehringer Ingelheim
Gold Track alumnus Ochre Bio has signed a landmark $1.3 billion collaboration with Boehringer Ingelheim to develop RNA-based therapies for liver disease.
News
Latest updates from ACI and the Gold Track portfolio.
Portfolio News
Eligo Bioscience Raises $30 Million for Genetic Medicines
Eligo Bioscience has raised $30 million to advance its precision genetic medicine platform using bacteriophage-based delivery.
Portfolio Exit
Exact Sciences Acquires OmicEra Diagnostics for €20M
OmicEra Diagnostics has been acquired by Exact Sciences for €20 million, delivering a successful exit for the Gold Track portfolio company.
Portfolio News
Ochre Bio Raises €30M for RNA-Based Liver Disease Therapies
Ochre Bio secured €30 million in Series A financing to advance its RNA-based therapeutic pipeline targeting chronic liver diseases.
ACI News
ACI Launches New Gold Track Cohort for 2023
ACI has selected a new cohort of high-potential life sciences companies for the Gold Track program, spanning biotech, medtech, and digital health.
Portfolio Exit
PhagoMed Acquired by BioNTech
PhagoMed, a phage-based therapeutics company and Gold Track graduate, has been acquired by BioNTech in a landmark exit.